Does the media favor DGX or HSIC?

In the previous week, Quest Diagnostics had 6 more articles in the media than Henry Schein. MarketBeat recorded 26 mentions for Quest Diagnostics and 20 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 0.97 beat Henry Schein's score of 0.52 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 18 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Henry Schein 5 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, DGX or MEDP?

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.04B 2.32 $992M $9.42 24.62 Medpace $2.53B 6.32 $451.12M $17.06 33.60

Is DGX or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.18% 16.01% 7.27% Medpace 17.67% 110.15% 24.84%

Does the media favor DGX or MEDP?

In the previous week, Quest Diagnostics and Quest Diagnostics both had 26 articles in the media. Medpace's average media sentiment score of 1.25 beat Quest Diagnostics' score of 0.97 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 18 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMN or DGX?

In the previous week, Quest Diagnostics had 17 more articles in the media than AMN Healthcare Services. MarketBeat recorded 26 mentions for Quest Diagnostics and 9 mentions for AMN Healthcare Services. Quest Diagnostics' average media sentiment score of 0.97 beat AMN Healthcare Services' score of 0.77 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 18 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LH or DGX?

In the previous week, Labcorp had 8 more articles in the media than Quest Diagnostics. MarketBeat recorded 34 mentions for Labcorp and 26 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.97 beat Labcorp's score of 0.75 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 11 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 18 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DGX or DVA more profitable?

Quest Diagnostics has a net margin of 9.18% compared to DaVita's net margin of 5.65%. Quest Diagnostics' return on equity of 16.01% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.18% 16.01% 7.27% DaVita 5.65% -270.37% 4.87%

Does the media favor DGX or DVA?

In the previous week, Quest Diagnostics had 8 more articles in the media than DaVita. MarketBeat recorded 26 mentions for Quest Diagnostics and 18 mentions for DaVita. DaVita's average media sentiment score of 1.01 beat Quest Diagnostics' score of 0.97 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 18 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DaVita 11 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quest Diagnostics (DGX) Competitors

$231.24 -1.78 (-0.76%)

As of 09:32 AM Eastern

Compare

DGX vs. HSIC, MEDP, AMN, LH, and DVA

Should you buy Quest Diagnostics stock or one of its competitors? MarketBeat compares Quest Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quest Diagnostics include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), and DaVita (DVA).

How does Quest Diagnostics compare to Henry Schein?

Quest Diagnostics (NYSE:DGX) and Henry Schein (NASDAQ:HSIC) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Quest Diagnostics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Quest Diagnostics has higher earnings, but lower revenue than Henry Schein. Quest Diagnostics is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.32	$992M	$9.42	24.62
Henry Schein	$13.18B	0.75	$398M	$3.31	26.14

Quest Diagnostics has a net margin of 9.18% compared to Henry Schein's net margin of 2.95%. Quest Diagnostics' return on equity of 16.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Henry Schein	2.95%	15.44%	5.53%

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 0.9% of Henry Schein shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Quest Diagnostics currently has a consensus price target of $235.31, indicating a potential upside of 1.45%. Henry Schein has a consensus price target of $89.36, indicating a potential upside of 3.29%. Given Henry Schein's stronger consensus rating and higher possible upside, analysts clearly believe Henry Schein is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Henry Schein	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

In the previous week, Quest Diagnostics had 6 more articles in the media than Henry Schein. MarketBeat recorded 26 mentions for Quest Diagnostics and 20 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 0.97 beat Henry Schein's score of 0.52 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	18 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	5 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Quest Diagnostics and Henry Schein tied by winning 8 of the 16 factors compared between the two stocks.

How does Quest Diagnostics compare to Medpace?

Quest Diagnostics (NYSE:DGX) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Quest Diagnostics presently has a consensus target price of $235.31, suggesting a potential upside of 1.45%. Medpace has a consensus target price of $584.18, suggesting a potential upside of 1.90%. Given Medpace's higher possible upside, analysts clearly believe Medpace is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Medpace	0 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.15

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.32	$992M	$9.42	24.62
Medpace	$2.53B	6.32	$451.12M	$17.06	33.60

In the previous week, Quest Diagnostics and Quest Diagnostics both had 26 articles in the media. Medpace's average media sentiment score of 1.25 beat Quest Diagnostics' score of 0.97 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	18 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats Quest Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Quest Diagnostics compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Quest Diagnostics (NYSE:DGX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

AMN Healthcare Services has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$3.42B	0.37	-$95.70M	-$0.87	N/A
Quest Diagnostics	$11.04B	2.32	$992M	$9.42	24.62

Quest Diagnostics has a net margin of 9.18% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Quest Diagnostics	9.18%	16.01%	7.27%

AMN Healthcare Services currently has a consensus target price of $29.00, indicating a potential downside of 12.13%. Quest Diagnostics has a consensus target price of $235.31, indicating a potential upside of 1.45%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Quest Diagnostics is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Quest Diagnostics had 17 more articles in the media than AMN Healthcare Services. MarketBeat recorded 26 mentions for Quest Diagnostics and 9 mentions for AMN Healthcare Services. Quest Diagnostics' average media sentiment score of 0.97 beat AMN Healthcare Services' score of 0.77 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	18 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services pays an annual dividend of $1.20 per share and has a dividend yield of 3.6%. Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.5%. AMN Healthcare Services pays out -137.9% of its earnings in the form of a dividend. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years. AMN Healthcare Services is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Quest Diagnostics beats AMN Healthcare Services on 14 of the 19 factors compared between the two stocks.

How does Quest Diagnostics compare to Labcorp?

Labcorp (NYSE:LH) and Quest Diagnostics (NYSE:DGX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Labcorp had 8 more articles in the media than Quest Diagnostics. MarketBeat recorded 34 mentions for Labcorp and 26 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.97 beat Labcorp's score of 0.75 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	11 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	18 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.9% of Labcorp shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 0.8% of Labcorp shares are held by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.5%. Labcorp pays out 23.8% of its earnings in the form of a dividend. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 14 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Quest Diagnostics has lower revenue, but higher earnings than Labcorp. Quest Diagnostics is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.81	$876.50M	$12.09	25.43
Quest Diagnostics	$11.04B	2.32	$992M	$9.42	24.62

Labcorp has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

Labcorp presently has a consensus price target of $326.00, suggesting a potential upside of 6.03%. Quest Diagnostics has a consensus price target of $235.31, suggesting a potential upside of 1.45%. Given Labcorp's stronger consensus rating and higher possible upside, analysts plainly believe Labcorp is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

Quest Diagnostics has a net margin of 9.18% compared to Labcorp's net margin of 6.99%. Labcorp's return on equity of 16.74% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.99%	16.74%	7.81%
Quest Diagnostics	9.18%	16.01%	7.27%

Summary

Labcorp beats Quest Diagnostics on 12 of the 19 factors compared between the two stocks.

How does Quest Diagnostics compare to DaVita?

Quest Diagnostics (NYSE:DGX) and DaVita (NYSE:DVA) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by company insiders. Comparatively, 1.9% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Quest Diagnostics has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.32	$992M	$9.42	24.62
DaVita	$13.64B	1.10	$746.80M	$10.78	21.65

In the previous week, Quest Diagnostics had 8 more articles in the media than DaVita. MarketBeat recorded 26 mentions for Quest Diagnostics and 18 mentions for DaVita. DaVita's average media sentiment score of 1.01 beat Quest Diagnostics' score of 0.97 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	18 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	11 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, DaVita has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Quest Diagnostics currently has a consensus price target of $235.31, suggesting a potential upside of 1.45%. DaVita has a consensus price target of $216.50, suggesting a potential downside of 7.25%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, research analysts clearly believe Quest Diagnostics is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
DaVita	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

Quest Diagnostics has a net margin of 9.18% compared to DaVita's net margin of 5.65%. Quest Diagnostics' return on equity of 16.01% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
DaVita	5.65%	-270.37%	4.87%

Summary

Quest Diagnostics beats DaVita on 10 of the 16 factors compared between the two stocks.

Get Quest Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DGX vs. The Competition

Export

Metric	Quest Diagnostics	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$25.72B	$9.93B	$6.86B	$23.73B
Dividend Yield	1.48%	2.54%	2.60%	4.21%
P/E Ratio	24.62	25.38	280.73	31.49
Price / Sales	2.32	4.90	643.21	14.39
Price / Cash	15.36	26.44	28.64	18.72
Price / Book	3.58	5.22	10.94	4.83
Net Income	$992M	$312.25M	$3.48B	$1.07B
7 Day Performance	-1.41%	-0.96%	0.78%	0.34%
1 Month Performance	7.71%	-0.91%	-4.20%	0.59%
1 Year Performance	34.39%	24.97%	61.51%	18.76%

Quest Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DGX Quest Diagnostics	4.3847 of 5 stars	$231.95 -0.5%	$235.31 +1.4%	+35.8%	$25.72B	$11.04B	24.62	57,000
HSIC Henry Schein	3.3453 of 5 stars	$84.61 -1.0%	$88.62 +4.7%	+27.3%	$9.74B	$13.18B	25.56	25,000	Earnings Report Analyst Upgrade
MEDP Medpace	2.9883 of 5 stars	$589.37 -2.0%	$560.92 -4.8%	+35.5%	$16.79B	$2.53B	34.55	6,200
AMN AMN Healthcare Services	1.8049 of 5 stars	$33.31 +1.3%	$29.00 -12.9%	+85.2%	$1.28B	$2.73B	N/A	2,664	Upcoming Earnings Analyst Downgrade
LH Labcorp	3.4074 of 5 stars	$301.03 +1.4%	$315.33 +4.8%	+17.6%	$24.34B	$13.95B	26.66	71,000	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DGX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and DVA

How does Quest Diagnostics compare to Henry Schein?

Summary

How does Quest Diagnostics compare to Medpace?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Summary

How does Quest Diagnostics compare to Labcorp?

Summary

How does Quest Diagnostics compare to DaVita?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and DVA

How does Quest Diagnostics compare to Henry Schein?

Which has more volatility and risk, DGX or HSIC?

Which has higher valuation & earnings, DGX or HSIC?

Is DGX or HSIC more profitable?

Do insiders & institutionals believe in DGX or HSIC?

Do analysts recommend DGX or HSIC?

Does the media favor DGX or HSIC?

Summary

How does Quest Diagnostics compare to Medpace?

Do analysts recommend DGX or MEDP?

Which has stronger valuation & earnings, DGX or MEDP?

Does the media favor DGX or MEDP?

Which has more volatility & risk, DGX or MEDP?

Do institutionals & insiders hold more shares of DGX or MEDP?

Is DGX or MEDP more profitable?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Which has more risk and volatility, AMN or DGX?

Which has stronger valuation & earnings, AMN or DGX?

Is AMN or DGX more profitable?

Do analysts rate AMN or DGX?

Do institutionals and insiders believe in AMN or DGX?

Does the media refer more to AMN or DGX?

Is AMN or DGX a better dividend stock?

Summary

How does Quest Diagnostics compare to Labcorp?

Does the media prefer LH or DGX?

Do insiders & institutionals believe in LH or DGX?

Is LH or DGX a better dividend stock?

Which has stronger earnings & valuation, LH or DGX?

Which has more volatility & risk, LH or DGX?

Do analysts rate LH or DGX?

Is LH or DGX more profitable?

Summary

How does Quest Diagnostics compare to DaVita?

Do insiders and institutionals believe in DGX or DVA?

Which has preferable valuation and earnings, DGX or DVA?

Does the media favor DGX or DVA?

Which has more risk & volatility, DGX or DVA?

Do analysts prefer DGX or DVA?

Is DGX or DVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools